Figure 5.

Post tumor formation therapy in efnb2^iΔEC knockout animals. (a) Median time until the neurological deficit was 19 days in the placebo-treated group (n = 9). No significant change detected after application of Ephrin-B2-Fc or NVP-BHG 712 (n = 11, 9, respectively, Log-rank (Mantel–Cox) test). Significance threshold adjusted for multiple comparisons by Bonferroni method. (b) Number of metastatic spinal cells in the placebo-treated group (n = 4) was not significantly affected by Ephrin-B2-Fc (n = 4) or NVP-BHG 712 (n = 4). (c) Mean number of spinal metastases remained unchanged (placebo n = 9, NVP-BHG 712 n = 11, EB2-Fc n = 9). No significant changes in mean individual and total tumor volume under therapy (One-way ANOVA with Dunnett’s multiple comparisons test, mean ± SEM for all experiments shown). (d) No. of tumor vessels was not significantly changed by therapy. Treatment with Ephrin-B2-Fc significantly reduced % of tumor area covered by vessels (n = 4, p = 0.0130). Tumor cell proliferation increased through NVP-BHG 712 administration (n = 2) and remained unaffected by Ephrin-B2-Fc administration (n = 5, one-way ANOVA with Dunnett’s multiple comparison test). (e) Representative images of confocal microscopy in spinal metastatic tumors. Staining and treatment as indicated. Mean ± SEM for all experiments are shown. One star (*) indicates p ≤ 0.05, two stars (**) indicate p ≤ 0.01 and three stars (***) indicate p ≤ 0.001.